Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 ...

Investing.com -- Shares of Allakos Inc . (NASDAQ:ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of ...

Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives – – Management to host conference call and webcast today at 8:30 am E.T ...

AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to ...

(NASDAQ:ALLK), a clinical-stage biotechnology company with a market capitalization of $108 million, announced today that it will halt the development of its drug candidate AK006 after it failed to ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). “While AK006 ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27. Thomas Smith’s rating is based on the recent disappointing results ...

Investing.com -- Shares of Allakos Inc . (NASDAQ:ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of therapeutic ...